Favourable Long-Term Outcomes in Stage II/III TNBC With Atezolizumab Added to Chemotherapy, ctDNA Dynamics Provide Prognostic Value Beyond pCR By Ogkologos - July 28, 2025 651 0 Facebook Twitter Google+ Pinterest WhatsApp Final results from the IMpassion031 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR EMA Recommends Granting a Marketing Authorisation for Tarlatamab April 17, 2026 2-Year-Old Cancer Survivor With Down Syndrome Hears For First Time: ‘Her... October 14, 2019 Efficacy and Safety of Patritumab Deruxtecan in Patients with EGFR-mutated NSCLC... September 29, 2023 Consensus on Conceptual Framework for Precision Cancer Medicine in Germany July 20, 2020 Load more HOT NEWS Pembrolizumab Now Second Immunotherapy Approved to Treat Merkel Cell Carcinoma FDA Expands Endometrial Cancer Indication for Dostarlimab-gxly with Chemotherapy How could proposed changes to data protection laws affect research? Study Offers Insights on Health Problems among AYA Cancer Survivors
